REGN · News · 20261112N
Revenue Performance and Mix
REGENERON PHARMACEUTICALS, INC. · 2026-11-12 · Importance 57 · Surprise 38
Regeneron’s reported revenue increased 36.3% year over year, and quarterly EPS was $20.07, according to multiple third-party reports. Third-quarter results were attributed to solid demand for Eylea HD and higher profit-sharing from Dupixent. Eylea sales declined while Eylea HD gained traction, helping offset the decline in Eylea sales.
Key facts
- Regeneron's third-quarter results were attributed to solid demand for Eylea HD and higher profit-sharing from Dupixent, which helped mitigate declining Eylea sales. source